Cite
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.
MLA
Okada, Annabelle A., et al. “Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.” Advances in Therapy, vol. 39, no. 6, June 2022, pp. 2984–98. EBSCOhost, https://doi.org/10.1007/s12325-022-02162-w.
APA
Okada, A. A., Takahashi, K., Ohji, M., Moon, S. C., Machewitz, T., Sasaki, K., The ALTAIR Study Investigators, Hanemoto, T., Kaga, T., Kouno, T., Kitamei, H., Sato, S., Yanai, R., Uchio, E., Miyata, K., Wakabayashi, Y., Maeno, T., Yasukawa, T., Horiguchi, M., & Nishimura, T. (2022). Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup. Advances in Therapy, 39(6), 2984–2998. https://doi.org/10.1007/s12325-022-02162-w
Chicago
Okada, Annabelle A., Kanji Takahashi, Masahito Ohji, SungChul Charles Moon, Tobias Machewitz, Koji Sasaki, The ALTAIR Study Investigators, et al. 2022. “Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.” Advances in Therapy 39 (6): 2984–98. doi:10.1007/s12325-022-02162-w.